We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen, Elan Report No New PML Cases in Tysabri Trials
Biogen, Elan Report No New PML Cases in Tysabri Trials
October 17, 2005
Biogen Idec and Elan have reported more positive news about their withdrawn multiple sclerosis (MS) drug Tysabri, announcing Oct. 17 that a safety analysis found no new cases of a rare brain disease among patients who took the drug to treat rheumatoid arthritis and Crohn’s disease.